ImageneBio (IMA) Cash & Equivalents (2020 - 2025)

ImageneBio has disclosed Cash & Equivalents across 6 years of filings, most recently posting $94.5 million for Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $94.5 million, up 680.1% year-over-year; the trailing twelve-month figure through Dec 2025 was $94.5 million (up 680.1% YoY), and the FY2025 annual result was $94.5 million, up 680.1% from the prior year.
• Cash & Equivalents came in at $94.5 million for Q4 2025 at ImageneBio, down from $103.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $281.0 million in Q1 2021 to a low of $12.1 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $63.5 million (2022), against an average of $101.7 million.
• Across the five-year window, Cash & Equivalents tumbled 89.89% in 2024 and soared 680.1% in 2025, its largest moves.
• ImageneBio's Cash & Equivalents stood at $232.2 million in 2021, then slumped by 74.2% to $59.9 million in 2022, then soared by 100.09% to $119.9 million in 2023, then sank by 89.89% to $12.1 million in 2024, then jumped by 680.1% to $94.5 million in 2025.
• The last three Cash & Equivalents figures came in at $94.5 million (Q4 2025), $103.2 million (Q3 2025), and $58.3 million (Q2 2025), per Business Quant data.